文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

膀胱癌诊断与治疗的纳米医学最新进展

State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer.

机构信息

Department of Urology, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen 518000, China.

Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.

出版信息

Biosensors (Basel). 2022 Sep 27;12(10):796. doi: 10.3390/bios12100796.

DOI:10.3390/bios12100796
PMID:36290934
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9599190/
Abstract

Bladder cancer is a common malignant tumor of the urinary system. Cystoscopy, urine cytology, and CT are the routine diagnostic methods. However, there are some problems such as low sensitivity and difficulty in staging, which must be urgently supplemented by novel diagnostic methods. Surgery, intravesical instillation, systemic chemotherapy, and radiotherapy are the main clinical treatments for bladder cancer. It is difficult for conventional treatment to deal with tumor recurrence, progression and drug resistance. In addition, the treatment agents usually have the defects of poor specific distribution ability to target tumor tissues and side effects. The rapid development of nanomedicine has brought hope for the treatment of bladder cancer in reducing side effects, enhancing tumor inhibition effects, and anti-drug resistance. Overall, we review the new progression of nano-platforms in the diagnosis and treatment of bladder cancer.

摘要

膀胱癌是泌尿系统常见的恶性肿瘤。膀胱镜检查、尿液细胞学检查和 CT 是常规诊断方法。然而，这些方法存在一些问题，如敏感性低和分期困难，这必须通过新的诊断方法来补充。手术、膀胱内灌注、全身化疗和放疗是膀胱癌的主要临床治疗方法。常规治疗很难应对肿瘤的复发、进展和耐药性。此外，治疗剂通常存在对肿瘤组织靶向能力差和副作用大的缺陷。纳米医学的快速发展为膀胱癌的治疗带来了希望，可以减少副作用、增强肿瘤抑制作用和抗耐药性。总的来说，我们综述了纳米平台在膀胱癌诊断和治疗方面的新进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d36/9599190/871a128b0f2b/biosensors-12-00796-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d36/9599190/e349938656b8/biosensors-12-00796-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d36/9599190/f819e0f6e979/biosensors-12-00796-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d36/9599190/6e132faa1195/biosensors-12-00796-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d36/9599190/1d8dbec0960c/biosensors-12-00796-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d36/9599190/d0298674d55c/biosensors-12-00796-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d36/9599190/da6c6e5efdba/biosensors-12-00796-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d36/9599190/4e9a55cce1ea/biosensors-12-00796-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d36/9599190/871a128b0f2b/biosensors-12-00796-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d36/9599190/e349938656b8/biosensors-12-00796-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d36/9599190/f819e0f6e979/biosensors-12-00796-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d36/9599190/6e132faa1195/biosensors-12-00796-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d36/9599190/1d8dbec0960c/biosensors-12-00796-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d36/9599190/d0298674d55c/biosensors-12-00796-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d36/9599190/da6c6e5efdba/biosensors-12-00796-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d36/9599190/4e9a55cce1ea/biosensors-12-00796-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d36/9599190/871a128b0f2b/biosensors-12-00796-g008.jpg

相似文献

[1]
State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer.

Biosensors (Basel). 2022-9-27

[2]
Recent Progress in Nanomaterial-Based Biosensors and Theranostic Nanomedicine for Bladder Cancer.

Biosensors (Basel). 2023-1-6

[3]
Diagnosis and management of superficial bladder cancer.

Curr Probl Cancer. 2001

[4]
Can the burden of follow-up in low-grade noninvasive bladder cancer be reduced by photodynamic diagnosis, perioperative instillations, imaging, and urine markers?

Curr Opin Urol. 2010-9

[5]
Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.

Urology. 2003-3

[6]
The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non-muscle-invasive bladder cancer: A preliminary results of randomized controlled trial.

Urol Oncol. 2018-11-14

[7]
Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.

Urol Oncol. 2016-10

[8]
Clinical application of drug sensitive gene detection in postoperative instillation for non-muscle invasive bladder cancer.

BMC Nephrol. 2020-10-7

[9]
Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.

Ann Chir Gynaecol. 2001

[10]
[Intravesical bacillus Calmette-Guerin instillation therapy of recurrent superficial bladder carcinomas resistant to intravesical anti-cancer chemotherapy].

Hinyokika Kiyo. 1989-4

引用本文的文献

[1]
Bladder cancer immune-related markers: diagnosis, surveillance, and prognosis.

Front Immunol. 2024

[2]
Nanomedicine in Bladder Cancer Therapy.

Int J Mol Sci. 2024-9-26

[3]
Trends in research on nanomedicine in urologic cancer: a bibliometric and visualized analysis.

Discov Oncol. 2024-8-23

[4]
Local Drug Delivery in Bladder Cancer: Advances of Nano/Micro/Macro-Scale Drug Delivery Systems.

Pharmaceutics. 2023-12-3

[5]
Sakuranin represses the malignant biological behaviors of human bladder cancer cells by triggering autophagy via activating the p53/mTOR pathway.

BMC Urol. 2023-10-24

[6]
A Large Genetic Causal Analysis of the Gut Microbiota and Urological Cancers: A Bidirectional Mendelian Randomization Study.

Nutrients. 2023-9-21

[7]
Cobalt Iron Oxide (CoFeO) Nanoparticles Induced Toxicity in Rabbits.

Vet Sci. 2023-8-9

[8]
The mechanism and clinical application of DNA damage repair inhibitors combined with immune checkpoint inhibitors in the treatment of urologic cancer.

Front Cell Dev Biol. 2023-5-25

[9]
Identifying stage-associated hub genes in bladder cancer via weighted gene co-expression network and robust rank aggregation analyses.

Medicine (Baltimore). 2022-12-23

本文引用的文献

[1]
Iron oxide@chlorophyll clustered nanoparticles eliminate bladder cancer by photodynamic immunotherapy-initiated ferroptosis and immunostimulation.

J Nanobiotechnology. 2022-8-11

[2]
Multi-responsive mesoporous polydopamine composite nanorods cooperate with nano-enzyme and photosensitiser for intensive immunotherapy of bladder cancer.

Immunology. 2022-10

[3]
Photo-Enhanced Chemotherapy Performance in Bladder Cancer Treatment via Albumin Coated AIE Aggregates.

ACS Nano. 2022-5-24

[4]
Paclitaxel/Chitosan Nanosupensions Provide Enhanced Intravesical Bladder Cancer Therapy with Sustained and Prolonged Delivery of Paclitaxel.

ACS Appl Bio Mater. 2018-12-17

[5]
Glyco-Coated CdSe/ZnS Quantum Dots as Nanoprobes for Carbonic Anhydrase IX Imaging in Cancer Cells.

ACS Appl Nano Mater. 2021-12-24

[6]
The value of contrast-enhanced ultrasound and magnetic resonance imaging in the diagnosis of bladder cancer.

J Cancer Res Ther. 2021-11

[7]
Role of Survivin in Bladder Cancer: Issues to Be Overcome When Designing an Efficient Dual Nano-Therapy.

Pharmaceutics. 2021-11-19

[8]
Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy.

J Immunother Cancer. 2021-11

[9]
Graphene Oxide and Graphene Quantum Dots as Delivery Systems of Cationic Porphyrins: Photo-Antiproliferative Activity Evaluation towards T24 Human Bladder Cancer Cells.

Pharmaceutics. 2021-9-18

[10]
Drug Release Profiles of Mitomycin C Encapsulated Quantum Dots-Chitosan Nanocarrier System for the Possible Treatment of Non-Muscle Invasive Bladder Cancer.

Pharmaceutics. 2021-8-31

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索